Page 86 - Read Online
P. 86
Canepa et al. Vessel Plus 2022;6:30 https://dx.doi.org/10.20517/2574-1209.2021.106 Page 13 of 13
PubMed PMC
76. Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation
2020;141:1214-24. DOI PubMed PMC
77. Gurwitz JH, Maurer MS. Tafamidis-a pricey therapy for a not-so-rare condition. JAMA Cardiol 2020;5:247-8. DOI PubMed
78. Psotka MA. Tafamidis should be accessible for all patients with transthyretin amyloid cardiomyopathy. JACC Heart Fail 2021;9:124-
6. DOI PubMed
79. Masri A, Chen H, Wong C, et al. Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in
history. JAMA Cardiol 2020;5:1066-7. DOI PubMed PMC
